Novartis faces growing pressure to drop patent case against Indian governmentBMJ 2007; 334 doi: http://dx.doi.org/10.1136/bmj.39132.422338.4E (Published 22 February 2007) Cite this as: BMJ 2007;334:383
- Sally Hargreaves
The Swiss drug company Novartis is under growing pressure from all sides as its long awaited High Court case against the Indian government began last month in Chennai.
Novartis is challenging the government's refusal of a patent for the leukaemia treatment imatinib (Glivec) and also section 3(d) of the Indian Patent Act, which restricts drug patents to innovative drugs. The law was designed to make it easier for poor patients to get cheaper generic drugs. If Novartis succeeds in the case, it would signal the start of more stringent patent laws in India and an end to the current trend of lower prices.
“People living with HIV from Lesotho to Laos depend on India …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial